October 1 ushered in a new era in U.S. foreign aid. What's the plan? Will it work? - NPR
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
In December, State Department senior official Jeremy Lewin welcomed Rwanda Foreign Minister Olivier J. P. Nduhungirehe for the signing of a multi-year Memorandum of Understanding on global health cooperation.
The Trump administration says that October 1 marks the dawn of a new era in global healthcare. It's the age of the "America First Global Health Strategy. " And that means rewriting the rules for funding healthcare in low- and middle-income countries. A key part of the "America First" strategy is the idea that the U. S. should not hand out billions of dollars for health and development programs without reaping concrete benefits — access to local minerals, for example — and without a commitment from governments to spend their own money. To be eligible for U. S. funds, each country is asked to sign a Memorandum of Understanding detailing the amount of money the U. S. will invest as well as the country's financial pledge.
This article is an excerpt. To read the full content, visit the original source. NPR
Related articles
Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!